康莱特注射液联合阿帕替尼治疗晚期胃癌的临床研究  

Study on Kanglaite injection combined with apatinib in the treatment of advanced gastric cancer

作　　者：刘登湘[1] 王娜[1] 何莉莉[1] 郭军[1] 孙雅薇 朱晓燕[1] 郭治[1] 靳毅[1] LIU Deng-xiang;WANG Na;HE Li-li;GUO Jun;SUN Ya-wei;ZHU Xiao-yan;GUO Zhi;JIN Yi(Department of Medicine Oncology,Xingtai People's Hospital,Xingtai 054031,Hebei,China)

机构地区：[1]邢台市人民医院肿瘤内科,河北邢台054031

出　　处：《川北医学院学报》2021年第1期38-41,共4页Journal of North Sichuan Medical College

基　　金：河北省中医药管理局科研计划项目(2018420)。

摘　　要：目的:研究康莱特注射液联合阿帕替尼治疗晚期胃癌的效果。方法:90例晚期胃癌患者分为两组,每组45例。对照组采用阿帕替尼化疗,试验组在此基础上联合康莱特注射液治疗。比较两组临床疗效、无进展生存期(PFS)、1年生存期(OS)、客观缓解率(ORR)、毒副反应发生率及生活质量改善情况。结果:化疗后比较,两组ORR比较差异无统计学意义(P>0.05);试验组血清白细胞介素2(IL-2)、干扰素-γ(INF-γ)和肿瘤坏死因子-α(TNF-α)水平均低于对照组(P<0.05);试验组0~Ⅳ级贫血、肝功能异常的毒副反应发生率低于对照组,试验组生活质量改善率高于对照组(P<0.05)。随访1年后,试验组PFS、OS均高于对照组(P<0.05)。试验组1年生存率略高于对照组,但差异无统计学意义(P>0.05)。结论:康莱特注射液联合阿帕替尼治疗晚期胃癌患者,可改善血清炎症因子水平、减少毒副反应,提高生活质量。Objective:To explore the effect of Kanglaite injection in apatinib chemotherapy for patients with advanced gastric cancer.Methods:A total of 90 patients with advanced gastric cancer were randomly divided into control group(apatinib chemotherapy)and experimental group(Kanglaite injection on basis of control group),45 cases in each group.The clinical curative effect,progression-free survival(PFS),1-year overall survival survival(OS),objective response rate(ORR),incidence of side reactions and improvement of quality of life were compared between the two groups.Results:After chemotherapy,there was no significant difference in ORR between experimental group and control group(P>0.05).After chemotherapy,levels of serum interleukin-2(IL-2),tumor necrosis factor-α(TNF-α)and interferon-γ(INF-γ)in experimental group were lower than those in control group(P<0.05).After chemotherapy,incidence of anemia at level 0~IV and abnormal liver function in experimental group was lower than that in control group,while improvement rate of quality of life was higher than that in control group(P<0.05).The patients in both groups were followed up for 1 year.PFS and OS in experimental group were higher than those in control group.The 1-year survival rate in experimental group was higher than that in control group,but the difference was not statistically significant(P>0.05).Conclusion:Kanglaite injection combined with apatinib in the treatment of patients with advanced gastric cancer can improve levels of serum inflammatory factors,reduce side effects,and improve quality of life.

关 键 词：胃癌 康莱特注射液 阿帕替尼 治疗效果 

分 类 号：R735.2[医药卫生—肿瘤]